Rhumbline Advisers Trims Holdings in Natera, Inc. (NASDAQ:NTRA)

Rhumbline Advisers lowered its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 1.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 138,281 shares of the medical research company's stock after selling 1,620 shares during the period. Rhumbline Advisers owned approximately 0.10% of Natera worth $21,890,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in NTRA. Gladstone Institutional Advisory LLC grew its stake in Natera by 1.7% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock valued at $574,000 after acquiring an additional 61 shares during the period. Silver Oak Securities Incorporated grew its stake in Natera by 3.1% in the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock valued at $470,000 after acquiring an additional 89 shares during the period. Covestor Ltd grew its stake in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after acquiring an additional 95 shares during the period. Blue Trust Inc. grew its stake in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after acquiring an additional 97 shares during the period. Finally, Hanseatic Management Services Inc. grew its stake in Natera by 12.0% in the fourth quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company's stock valued at $158,000 after acquiring an additional 107 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Stock Performance

Natera stock traded down $5.88 during mid-day trading on Friday, reaching $162.31. 1,604,242 shares of the company's stock were exchanged, compared to its average volume of 1,342,687. The business's fifty day simple moving average is $168.06 and its 200 day simple moving average is $144.78. The firm has a market capitalization of $21.43 billion, a PE ratio of -92.22 and a beta of 1.66. Natera, Inc. has a one year low of $69.74 and a one year high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 663 shares of the firm's stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares of the company's stock, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Michael Burkes Brophy sold 43,502 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76. Following the completion of the sale, the chief financial officer now directly owns 70,629 shares of the company's stock, valued at $12,492,857.52. This represents a 38.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 295,772 shares of company stock valued at $49,741,699 over the last ninety days. 7.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have commented on NTRA. Canaccord Genuity Group raised their price objective on Natera from $165.00 to $180.00 and gave the company a "buy" rating in a research note on Friday, January 3rd. Piper Sandler raised their target price on Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a report on Monday, November 18th. Sanford C. Bernstein raised their target price on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, January 10th. JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, December 13th. Finally, TD Cowen raised their target price on Natera from $155.00 to $175.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Natera has an average rating of "Moderate Buy" and an average target price of $170.94.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.